文献速递心胸血管麻醉

衰竭心脏左心室心肌组织局部阿片系统分析

Analysis of the Local Opioid System in Human Left Ventricular Myocardial Tissue from Failing Hearts.
PubMed 文献 · Anesth Analg · 2025-09-15

本研究利用生物样本库左心室心肌组织,比较扩张型心肌病(DCM,LVEF中度或重度降低)与肥厚型梗阻性心肌病(HOCM,LVEF保留)患者阿片受体及前体肽表达。Real-time PCR和Western blot检测DOR、KOR、MOR及PENK、PDYN、POMC,免疫组化验证受体存在。KOR基因表达差异效应量0.93,MOR蛋白差异效应量0.62,但均无统计学显著性(P > .05)。

要点

  • 人左心室心肌表达阿片受体DOR、KOR、MOR及前体肽PENK,支持内源性心脏阿片系统存在。
  • DCM与HOCM间KOR基因(效应量0.93)和MOR蛋白(效应量0.62)差异未达统计学显著。
  • DOR、MOR、PDYN mRNA在终末期左心室心肌病中低于检测水平。

核心结论

  • 人左心室心肌组织存在阿片受体与阿片肽,支持内源性心脏阿片系统。
  • 不同心肌病亚型间基因或蛋白表达无统计学显著差异,提示表达模式大致均一或疾病相关变化细微。

研究设计与样本

  • 生物样本库左心室心肌组织,来自DCM心脏移植或左心室辅助装置植入患者及HOCM室间隔切除术患者。
  • 按心肌病类型和LVEF分组:DCM LVEF中度降低(20%-35%)、DCM LVEF重度降低(<20%)、HOCM LVEF保留(>55%)。
  • Real-time PCR和Western blot分析阿片受体及前体肽表达,免疫组化评估受体表达。

主要发现

  • Real-time PCR可检测KOR、PENK、POMC mRNA,而DOR、MOR、PDYN mRNA低于检测水平。
  • Western blot确认DOR、KOR、MOR和PENK蛋白表达。
  • DCM与HOCM比较,KOR基因表达差异效应量0.93,MOR蛋白表达差异效应量0.62。
  • 上述差异均未达到统计学显著性(P > .05)。
  • 免疫组化证实死后人左心室心肌组织存在阿片受体。

关键数值与推荐

  • DCM LVEF中度降低定义为20%-35%。
  • DCM LVEF重度降低定义为<20%。
  • HOCM LVEF保留定义为>55%。
  • KOR基因表达组间差异效应量0.93。
  • MOR蛋白表达组间差异效应量0.62。

临床怎么用

  • 提示心脏本身存在阿片系统,围术期阿片类药物作用可能涉及心脏局部机制。
  • 心肌病亚型间阿片受体表达无显著差异,不支持据此进行亚型个体化阿片用药。
  • 心衰患者围术期阿片管理仍需依据临床评估,本研究未提供剂量或疗效依据。

局限性

  • 样本来自生物样本库,DCM与HOCM患者来源手术不同。
  • DOR、MOR、PDYN mRNA低于检测水平,限制相应基因表达分析。
  • 部分免疫组化使用死后心肌组织。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The increasing age of surgical patients is associated with a higher prevalence of chronic pain and cardiovascular comorbidities, including heart failure (HF). Recent studies suggest the existence of an intrinsic cardiac opioid system that may be dynamically regulated during HF. This study investigated left ventricular myocardial tissue from patients with end-stage dilated (DCM) and/or hypertrophic obstructive cardiomyopathy (HOCM) to assess whether the expression of opioid receptors and their endogenous ligand precursor peptides varies with cardiomyopathy type and severity. It was hypothesized that the cardiac opioid system is differentially regulated in DCM and HOCM, reflecting disease-specific remodeling. METHODS: Left ventricular myocardial tissue was obtained from a biobank. Samples had previously been collected from patients with DCM who had undergone heart transplantation or left ventricular assist device implantation, and from HOCM patients who had undergone surgical myectomy. Patients were grouped by cardiomyopathy type and left ventricular ejection fraction (LVEF): DCM with moderate (20%-35%) or severely reduced (<20%) LVEF, and HOCM with preserved LVEF (>55%). Gene and protein expression of the opioid receptors delta (DOR), kappa (KOR), and mu (MOR), as well as their endogenous ligand precursors proenkephalin (PENK), prodynorphin (PDYN), and proopiomelanocortin (POMC), were analyzed by real-time PCR and western blot, respectively. In addition, opioid receptor expression was assessed by immunohistochemistry in postmortem human hearts. RESULTS: KOR, PENK, and POMC mRNA were detected by real-time PCR, while DOR, MOR, and PDYN mRNA were below detection in end-stage left ventricular cardiomyopathy. Western blot analysis confirmed protein expression of DOR, KOR, MOR, and PENK. When comparing DCM to HOCM samples, KOR gene expression showed the largest difference (effect size: 0.93), and MOR protein expression showed a moderate difference (effect size: 0.62). However, none of the differences reached statistical significance ( P > .05). Immunohistochemistry confirmed the presence of opioid receptors in postmortem human myocardial tissue of the left ventricle. CONCLUSIONS: This study confirms the presence of opioid receptors and opioid peptides in human left ventricular myocardial tissue, supporting the existence of an intrinsic cardiac opioid system. However, no statistically significant differences in gene or protein expression were observed between cardiomyopathy subtypes. These neutral findings suggest a largely uniform expression pattern across cardiomyopathy subtypes or only subtle disease-related changes and warrant further investigation into the potential role of the cardiac opioid system in HF pathophysiology.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Lasch A, Shahin K, Shaqura M, et al. Analysis of the Local Opioid System in Human Left Ventricular Myocardial Tissue from Failing Hearts. Anesth Analg. 2025. PMID: 40952062. doi:10.1213/ANE.0000000000007744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。